无症状瓣膜性心脏病干预时机
本文综述无症状瓣膜性心脏病干预时机的当前推荐与最新数据。早期干预旨在预防不可逆左室心肌改变,但需权衡干预风险与长期后果。新兴风险标志包括极重度瓣膜梗阻、利钠肽升高及心肌纤维化证据;TAVI目前不推荐用于无症状重度主动脉瓣狭窄。
要点
- 早期干预主要理由为预防不可逆左室心肌改变及后续不良事件。
- 无症状重度主动脉瓣狭窄的新兴风险标志包括极重度梗阻、利钠肽升高和心肌纤维化。
- 二尖瓣狭窄经导管球囊瓣膜切开术使干预天平倾向更早以预防房颤、栓塞和肺高压。
核心结论
- 无症状瓣膜性心脏病的最佳干预时机是不断变化的阈值,取决于瓣膜病严重程度及治疗选项的安全性、疗效和长期耐久性。
研究设计与样本
- 综述总结了当前推荐并讨论了近期发表的数据。
主要发现
- 无症状主动脉瓣狭窄的新兴风险标志包括极重度瓣膜梗阻、血清利钠肽水平升高及心肌纤维化或细胞外心肌体积增加的影像学证据。
- 无症状重度主动脉瓣狭窄目前不推荐经导管主动脉瓣植入术治疗,但未来可能改变。
- 主动脉瓣反流早期干预预防左室扩张和功能障碍的潜在获益需与人工瓣膜长期风险平衡,尤其年轻先天性二叶瓣患者。
- 二尖瓣狭窄经导管二尖瓣球囊瓣膜切开术选项使干预天平倾向更早以预防房颤、栓塞事件和肺高压。
- 慢性重度二尖瓣反流由二尖瓣脱垂所致时,解剖特征符合高可能成功且持久瓣膜修复者支持早期干预。
临床怎么用
- 对无症状瓣膜性心脏病患者,应个体化权衡早期干预潜在获益与干预风险及长期后果。
- 决策时可参考新兴风险标志如极重度瓣膜梗阻、利钠肽升高和心肌纤维化证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current management of valvular heart disease (VHD) seeks to optimize long-term outcome by timely intervention. Recommendations for treatment of patients with symptoms due to severe valvular disease are based on a foundation of solid evidence. However, when to intervene in asymptomatic patients remains controversial and decision requires careful individual weighing of the potential benefits against the risk of intervention and its long-term consequences. The primary rationale for earlier intervention is prevention of irreversible left ventricular (LV) myocardial changes that might result in later clinical symptoms and adverse cardiac events. A number of outcome predictors have been identified that facilitate decision-making. This review summarizes current recommendations and discusses recently published data that challenge them suggesting even earlier intervention. In adults with asymptomatic aortic stenosis (AS), emerging risk markers include very severe valve obstruction, elevated serum natriuretic peptide levels, and imaging evidence of myocardial fibrosis or increased extracellular myocardial volume. Currently, transcatheter aortic valve implantation (TAVI) is not recommended for treatment of asymptomatic severe AS although this may change in the future. In patients with aortic regurgitation (AR), the potential benefit of early intervention in preventing LV dilation and dysfunction must be balanced against the long-term risk of a prosthetic valve, a particular concern because severe AR often occurs in younger patients with a congenital bicuspid valve. In patients with mitral stenosis, the option of transcatheter mitral balloon valvotomy tilts the balance towards earlier intervention to prevent atrial fibrillation, embolic events, and pulmonary hypertension. When chronic severe mitral regurgitation is due to mitral valve prolapse, anatomic features consistent with a high likelihood of a successful and durable valve repair favour early intervention. The optimal timing of intervention in adults with VHD is a constantly changing threshold that depends not only on the severity of valve disease but also on the safety, efficacy, and long-term durability of our treatment options.
引用
- Baumgartner H, Iung B, Otto CM, et al. Timing of intervention in asymptomatic patients with valvular heart disease. Eur Heart J. 2020. PMID: 32901279. doi:10.1093/eurheartj/ehaa485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。